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ABSTRACT (250 words) 
Introduction: Metabolic syndrome (MetS) has been associated with lower bone turnover and 
relative bone mass or strength deficits (i.e. not proportionate to body mass index, BMI), but 
the relative contributions of MetS components related to insulin sensitivity or obesity to male 
bone health remain unclear. 
Methods: We determined cross-sectional associations of MetS, its components and insulin 
sensitivity (by homeostatic model assessment, HOMA-S) using linear regression models 
adjusted for age, center, smoking, alcohol and BMI. Bone turnover markers and heel 
broadband ultrasound attenuation (BUA) were measured in 3129 men aged 40-79. Two 
centers measured total hip, femoral neck and lumbar spine areal bone mineral density 
(aBMD, n=527) and performed radius peripheral quantitative computed tomography (pQCT, 
n=595). 
Results: MetS was present in 975 men (31.2%). Men with MetS had lower β-CTX, PINP and 
osteocalcin (P<0.0001) and higher total hip, femoral neck and lumbar spine aBMD (P≤0.03). 
Among MetS components, only hypertriglyceridemia and hyperglycemia were independently 
associated with PINP and β-CTX. Hyperglycemia was negatively associated with BUA, 
hypertriglyceridemia with hip aBMD and radius CSA and stress-strain index. HOMA-S was 
similarly associated with PINP and β-CTX, BUA and radius CSA in BMI-adjusted models. 
Conclusions: Men with MetS have higher aBMD in association with their greater body mass, 
while their lower bone turnover and relative deficits in heel BUA and radius CSA are mainly 
related to correlates of insulin sensitivity. Our findings support the hypothesis that underlying 
metabolic complications may be involved in bone’s failure to adapt to increasing bodily loads 
in men with MetS. 
Keywords: Bone mineral density, bone turnover, male, metabolic syndrome, obesity, 
peripheral quantitative computed tomography   
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Summary: (50 words) 
We examined cross-sectional associations of metabolic syndrome and its components with 
male bone turnover, density and structure. Greater bone mass in men with metabolic 
syndrome was related to their greater body mass, whereas hyperglycemia, 
hypertriglyceridemia or impaired insulin sensitivity were associated with lower bone turnover 
and relative bone mass deficits. 
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Introduction 
The metabolic syndrome (MetS) encompasses several features –abdominal obesity, elevated 
blood pressure, dyslipidemia and hyperglycemia– which confer an increased risk of 
developing cardiovascular disease and type 2 diabetes mellitus (T2D) [1]. The usefulness of 
the MetS concept relies on the assumptions that (i) all components are important and treatable 
predictors of adverse cardiometabolic outcomes, (ii) MetS predicts these outcomes better than 
the sum of its individual components, and (iii) MetS predicts these outcomes better than 
simpler measures like body mass index (BMI). Indeed, instead of focusing on obesity, 
correlates (or consequences) of insulin resistance (hyperglycemia, hypertriglyceridemia) lie at 
the heart of the MetS concept [2]. Although MetS may be a useful construct to focus 
cardiovascular and T2D preventive strategies, the validity of this construct as well as its cut-
off values remain debated. Nevertheless, all MetS components become increasingly prevalent 
with age, with around 25-35% of adults having MetS (depending on the definition and 
population studied) [3-7]. 
Osteoporosis is also a common age-related condition. With a male lifetime incidence of 
osteoporotic fractures as high as 20-25% in high-risk Caucasian populations, men contribute 
substantially to the overall fracture burden [8]. Contrary to the general belief that obesity is 
protective for the skeleton, a growing body of evidence suggests that the relationships 
between bone metabolism, obesity and insulin resistance are more complex. Both obesity and 
T2D have been associated with higher areal bone mineral density (aBMD) [9, 10], which 
however does not seem to confer protection against fractures [11-13]. This paradox may be 
explained by higher falls risk and impact force, altered material properties [14] as well as 
relative deficits in cortical bone structure and strength [10, 14-17]. This relative bone deficit 
involves greater absolute aBMD, cross-sectional bone area or volumetric BMD (vBMD) with 
increasing BMI [10], whereas associations of MetS or T2D with bone outcomes become 
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negative in BMI-adjusted models [3-5, 7, 9] i.e. BMD or bone strength not being as high in 
MetS or T2D as would be expected based on BMI alone. In other words, bone strength adapts 
to increasing bodily loads, but this relationship becomes attenuated at higher levels of BMI. 
In a recent MrOS study for example, estimated hip bone strength increased linearly with BMI 
until it started to plateau around BMI 30 kg/m² [16]. Why the skeletal strength:load ratio 
flattens in obesity is incompletely understood, but metabolic complications may be involved 
since previous studies on MetS have consistently reported negative associations of MetS 
components with aBMD in BMI-adjusted models [7]. Given the high prevalence of obesity 
and MetS, a deeper understanding of their relation to bone turnover, aBMD and vBMD, bone 
structure and bone strength can offer potentially important insights into male bone health. 
Using data from the observational European Male Ageing Study (EMAS), we examined 
associations of MetS, its components as well as insulin sensitivity (HOMA-S) with bone 
turnover markers (BTMs), heel quantitative ultrasound (QUS), hip and spine aBMD and 
radius peripheral computed tomography (pQCT) measures. 
Methods 
Participants 
The design, cohort profile and assessments of EMAS have been reported previously [18]. 
From 2003 to 2005, an age-stratified random population sample of men aged 40-79 was 
recruited by eight European centers: Manchester, United Kingdom; Leuven, Belgium; 
Malmö, Sweden; Tartu, Estonia; Łódź, Poland; Szeged, Hungary; Florence, Italy and 
Santiago de Compostela, Spain. Ethical approval was obtained according to local institutional 
requirements at all centers and all men provided written informed consent. 
Study questionnaires and clinical assessments 
Subjects completed a postal questionnaire which included questions about comorbidities, 
smoking and average number of days per week in which alcohol was consumed in the 
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previous month. Standardized measurements were taken for height to the nearest mm using a 
stadiometer (Leicester Height Measure, SECA UK Ltd) and body weight to the nearest 0.1 kg 
using an electronic scale (SECA, model 8801321009), with monthly calibrations in each 
center. BMI was calculated as weight in kilograms divided by height (in meters) squared. 
Waist circumference was measured using anthropometric tape midway between the iliac crest 
and lowest ribs, and the median of three measurements was recorded. Seated blood pressure 
(Omron 500I, Omron Healthcare Ltd, Milton Keynes, UK) was measured after a 5 min rest 
period. Reuben’s Physical Performance Test (PPT) was assessed as time (in seconds) 
required for a 50-feet walk. Interviewer-assisted questionnaires included prescription and 
non-prescription medication, and the Physical Activity Scale for the Elderly (PASE). 
Biological measurements 
A fasting morning (before 10:00 a.m.) venous blood sample was obtained, from which serum 
was separated and stored at -80 °C until analysis. Methods of measurement for BTMs and 
hormones have been described in detail previously [19, 20]. Serum β C-terminal cross-linked 
telopeptide (β-CTX; β-Crosslaps, n=3018), N-terminal propeptide of type I procollagen 
(PINP, n=3020) and osteocalcin (stable N-MID fragment, n=1089 randomly selected 
subjects) were measured by electrochemiluminescence immunoassay (ECLIA) on the Elecsys 
2010 automated analyser (Roche Diagnostics) [21]. The detection limits of these kits are 10 
pg/ml, < 5 ng/ml and 0.5 ng/ml, and the intra-assay coefficient of variation (CV) < 5.0 %, 
<3.0 % and < 5.0 % for β-cTX, P1NP and osteocalcin, respectively. Glucose, cholesterol and 
triglyceride measurements were undertaken in each participating center. Insulin was assayed 
using quimioluminiscence at University of Santiago de Compostela. Indices of insulin 
resistance, sensitivity and bèta-cell mass were calculated using the homeostasis model 
assessment (HOMA-IR, HOMA-S, HOMA-B, respectively) [22]. The quantitative insulin 
sensitivity check index (QUICKI) was calculated as the inverse of the sum of the logarithms 
9 
 
of fasting glucose and insulin concentrations [23]. Methods for other hormone measurements 
in EMAS have been reported previously [20, 24, 25]. 
Definition of metabolic syndrome (MetS) 
MetS was defined according to the 2009 harmonized criteria [1]. Subjects were classified as 
having MetS (MetS+) when ≥ 3 of the following criteria were present: waist circumference > 
102 cm, triglycerides ≥ 1.7 mmol/l (150 mg/dl), HDL cholesterol < 1.03 mmol/l (40 mg/dl), 
systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg or use of 
antihypertensive drugs, and fasting glucose ≥ 5.6 mmol/l (100 mg/dl) or use of antidiabetic 
drugs. In the analyses comparing MetS+ to MetS- subjects, those with missing data were 
excluded when MetS could not be classified with certainty [25]. 
Quantitative ultrasound (QUS) of the heel 
In all centers, QUS of the left heel was performed with the Sahara Clinical Sonometer 
(Hologic, Inc., Waltham, MA, USA) using a standardized protocol [19]. Each center 
calibrated the device daily with the physical phantom provided by the manufacturer. All 
quality control results were sent to Leuven and found stable throughout the study. Outputs 
included broadband ultrasound attenuation (BUA), speed of sound (SOS), estimated BMD 
(eBMD = 0.002592 × (BUA+SOS) − 3.687) and quantitative ultrasound index (QUI, a 
measure of stiffness calculated as QUI = 0.41[SOS]  + 0.41[BUA] − 571). Short-term 
precision of the method was established by duplicate measurements performed in 20 
randomly selected cohort members in Leuven. The in vivo CVs were 2.8, 0.3 and 2.3% for 
BUA, SOS and QUI, respectively. Ten repeat measurements were performed on a roving 
phantom at each center. Standardized CVs (root mean squared difference divided by range to 
mean ratio [26]) for within machine variability ranged by center: for SOS, from 1.0 to 5.6%, 
and BUA from 0.7 to 2.7%. Standardized CVs for between machine variability were 4.8% for 
BUA and 9.7% for SOS. 
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Dual-energy X-ray absorptiometry (DXA) and radius pQCT 
Subjects in Leuven and Manchester had DXA and pQCT scans performed. For DXA, the 
same QDR 4500A Discovery scanners were used in both centers (Hologic Inc, Bedford, MA, 
USA). Lumbar spine (L1–4), femoral neck and total hip aBMD were measured as described 
previously [19]. All scans and analyses were performed by trained and certified DXA 
technicians. The Hologic spine phantom was scanned daily to monitor the device 
performance and long-term stability. The precision errors (CV%) were 0.57% and 0.97% at 
L1-4, 1.28% and 2.04% at the femoral neck, and 0.56% and 0.97% at the total proximal 
femur in Leuven (n=20) and Manchester (n=31), respectively. Devices in Leuven and 
Manchester were cross-calibrated with the European spine phantom. 
The pQCT protocol has been described previously [24]. In both centers, the non-dominant 
radius was measured using an XCT-2000 scanner (Stratec, Pforzheim, Germany) following 
the manufacturer's standard quality assurance procedures. Total and trabecular vBMD 
(mg/mm3), trabecular area and total cross-sectional area (CSA) (mm2) were measured at the 
distal (4%) radius (voxel size 0.4 mm). Cortical vBMD (mg/mm3), total CSA, cortical and 
medullary area (mm2), cortical thickness (mm), stress strain index (SSI) (mm3) and muscle 
CSA (mm2) were measured at the midshaft (50%) radius (voxel size 0.6 mm). The European 
Forearm Phantom (EFP) was measured in both centers; 10 repeat measurements were taken 
in slices 1–4. Differences were less than precision error for total, trabecular and cortical 
vBMD, and cortical area; therefore, cross-calibration was omitted. The short term precision of 
2 repeat measurements with repositioning were: total vBMD 2.1% and 1.3%; trabecular 
vBMD 1.27% and 1.42%; cortical vBMD 0.77% and 0.71%; and cortical area 2.4% and 1.3% 
in Manchester (n = 22) and Leuven (n = 40), respectively. 
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Statistical analyses 
Cross-sectional differences between MetS+ and MetS- groups were assessed by Mann-
Whitney U-test and chi-square for continuous and categorical variables, respectively. Linear 
regression analysis of the association between metabolic (independent) and bone (outcome) 
variables were performed (i) unadjusted, (ii) adjusted for potential confounders (age, center, 
smoking and alcohol intake), (iii) adjusted for these confounders plus other MetS components 
(to examine whether individual MetS component demonstrate associations independent of 
other MetS components), or (iv) adjusted for confounders plus BMI. Associations are 
reported as standardized (z-score) β regression coefficients. Analyses were performed using 
Stata version 13.1 (StataCorp, College Station, TX, USA), and two-tailed P < 0.05 was 
considered significant. No adjustments for multiple testing were applied. 
Results 
Study population and characteristics 
Of 3369 men in the baseline cohort, we excluded men taking glucocorticoids, drugs with 
possible hormonal effects (incl. sex steroids, gonadorelin analogues, strong opioids, and 
drugs for thyroid disorders), bone-active treatments (incl. bisphosphonates, calcium and/or 
vitamin D supplements), HIV drugs or men in whom MetS status could not be determined 
due to missing values. The total number of exclusion was 240 (7.12%), leaving 3129 men in 
the analytical sample. Of these, 975 (31.2%) were classified as having MetS, i.e. satisfying at 
least three MetS criteria. There were 257 (8.2%), 961 (30.7%), 936 (29.9%), 627 (20.0%), 
284 (9.1%) and 64 (2.0%) men satisfying exactly 0, 1, 2, 3, 4 or 5 MetS criteria, respectively. 
Apart from having more MetS features, men with MetS were older, heavier, more often 
former smokers and less frequent drinkers (Table 1). They also had an altered endocrine 
profile, walked slower and reported less physical activity (Supplemental Table 1). 
Associations between MetS, its components and bone turnover markers  
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Men with MetS had significantly lower levels of PINP, osteocalcin and particularly β-CTX 
(Table 1). In linear regression analyses, MetS (Table 2) was associated with lower BTMs, 
independent of confounders (age, center, smoking and alcohol; Model 1) and BMI (Model 3), 
except for osteocalcin. However, when MetS components were analyzed individually, only 
hypertriglyceridemia and hyperglycemia were inversely associated with PINP and β-CTX, 
independent from other MetS components (Model 2) or BMI (Model 3). Osteocalcin was 
independently and inversely associated only with hyperglycemia (Model 3). Also when 
analyzed as continuous variables, glucose and triglycerides showed independent inverse 
associations with β-CTX, PINP and osteocalcin, whereas blood pressure, HDL and waist 
circumference did not (data not shown). Insulin sensitivity (HOMA-S or QUICKI) was also 
associated with PINP and β-CTX, independently of age, center, smoking, alcohol and BMI 
(Supplemental Table 2). Adjustment for differences  in either physical activity/performance, 
sex steroids, PTH, 25-OH-vitamin D, IGF-1 or CRP (Supplemental Table 1) did not alter the 
associations between MetS and BTMs (data not shown). Compared to the referent group of 
men satisfying exactly two MetS criteria, men with three, four or five MetS criteria had lower 
BTMs (Suppl. Fig. 1A-B). However, men with one or zero criteria also had higher BTMs, 
implying that there is no clear threshold at three MetS criteria above which BTMs are altered. 
Associations between MetS, its components and heel QUS parameters  
Following adjustment for age, center, smoking and alcohol, MetS was positively associated 
with BUA and QUI (Table 3) but not SOS or eBMD (data not shown). When adjusted for 
BMI however, these associations became non-significant. When individual MetS components 
were examined (Table 3), only waist >102 cm was positively associated with BUA and QUI 
(as well as SOS and eBMD, not shown), although not independently from BMI. In fact, BMI 
adjustment (Model 3) revealed a negative association of hyperglycemia with BUA. Also 
when analyzed as continuous variables, glucose and triglycerides where inversely associated 
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with BUA and QUI the BMI-adjusted model (data not shown). Fasting insulin levels and 
markers of insulin resistance were also negatively associated with BUA, SOS, QUI and 
eBMD, but again this was only evident following BMI adjustment (Supplemental Table 2). 
BMI itself was positively associated with QUS parameters (Supplemental Table 2). 
Adjustment for differences  in either physical activity/performance, sex steroids, PTH, 25-
OH-vitamin D, IGF-1 or CRP (Supplemental Table 1) did not affect the associations between 
MetS and QUS parameters (data not shown). Men with four MetS criteria had significantly 
higher BUA and QUI compared to the referent group of men satisfying two MetS criteria in 
unadjusted and confounder-adjusted analyses, but this was not the case for men meeting all 
five MetS criteria (Suppl. Fig. 1C-D). In fact, adjustment for BMI revealed significantly 
lower BUA and QUI in men with full MetS. 
Associations of MetS and its components with aBMD and pQCT outcomes 
A subgroup of men from Manchester and Leuven underwent DXA (n=527) and radius pQCT 
(n=595). Men with MetS had higher aBMD at the lumbar spine, total hip and femoral neck 
(Table 1). MetS was positively associated with aBMD at all three sites independent of 
confounders, but not following BMI adjustment (Table 4). Among MetS components, waist > 
102 cm and hyperglycemia were independently associated with aBMD at all three sites, but 
not independent from BMI (Table 4). Interestingly, hypertriglyceridemia was inversely 
associated with femoral neck aBMD when adjusted for other MetS components or BMI. 
Men with MetS had higher muscle area, with a trend towards greater cortical bone area 
(P=0.053) and lower muscle density (P=0.06) (Table 1). In linear regression analyses, MetS 
as a whole was not associated with skeletal pQCT parameters (data not shown). Among MetS 
components, waist circumference was independently associated with greater CSA at the 
ultradistal (not shown) and midcortical site, cortical thickness and bone area, SSI and muscle 
area (Table 4). Hypertriglyceridemia (or triglycerides as a continous variable, data not 
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shown) was negatively associated with CSA and SSI independent from other MetS 
components or BMI, and with cortical bone area when adjusted for BMI (Table 4). Both at 
the ultradistal and mid-radius, MetS or its components were not associated with vBMD (data 
not shown). Cortical bone area, CSA and SSI were also associated with HOMA-S and 
QUICKI, but only in BMI-adjusted models (Supplemental Table 2). 
Discussion 
MetS is fairly common in the general population; in line with previous studies [3-7, 9], 
almost one-third of our 40-79 year-old European men qualified under recent international 
criteria [1]. Our main findings are that in men with MetS, the lower bone turnover and greater 
bone mass at loaded sites (as reflected by heel BUA and total hip, femoral neck and lumbar 
spine aBMD) are not uniformly associated with all MetS components. The lower bone 
turnover was mainly associated with MetS components related to insulin sensitivity 
(hyperglycemia, hypertriglyceridemia) or indices thereof (HOMA-S, QUICKI). On the other 
hand, the association of MetS with greater bone mass was determined by greater body mass 
(either by waist circumference or BMI) and not present at the radius, despite greater forearm 
muscle area. The associations of MetS with lower BTMs and superior QUS parameters in the 
overall cohort did not appear to be explained by higher free/bioavailable E2 levels (data not 
shown) and occurred in spite of an otherwise adverse endocrine/biochemical profile in men 
with MetS (Supplementary Table 1). 
There is agreement in the literature that MetS is not an overall valid construct in relation to 
bone health because not all components of MetS have similar associations with skeletal 
outcomes [3, 5, 9]. Previous studies in older men have shown that MetS or hyperglycemia are 
inversely associated with BTMs as the outcome [5, 6, 27]. However, these studies have not 
reported association of individual MetS components with BTMs independent from other 
MetS components. Our finding that not only hyperglycemia but also hypertriglyceridemia 
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was independently associated with BTMs is of interest given that triglycerides were strongly 
related to aBMD and fracture risk in two previous studies [3, 5]. We reasoned that insulin 
sensitivity could explain the association with hyperglycemia and hypertriglyceridemia, and 
indeed found that indices like HOMA-S and QUICKI were independently associated with 
bone turnover (Supplementary Table 2). The finding that men with greater waist 
circumference or BMI have higher absolute heel QUS parameters, hip and spine aBMD and 
mid-radius cortical bone and muscle area are also in accordance with previous studies [3, 9, 
10, 12, 13, 16] and consistent with the hypothesis that bone mass in obesity is adapted to 
greater bodily loads. 
Importantly however, adjusting for BMI revealed inverse associations of hyperglycemia with 
heel BUA, and of hypertriglyceridemia with aBMD at the total hip, femoral neck as well as 
radius cortical bone area, CSA and SSI. This is in agreement with previous observations in 
T2D [11, 15] and several studies on MetS and male bone health [3-5, 9] which also found 
aBMD, bone width or strength to be increased in absolute terms, but not in BMI-adjusted 
models i.e. not as much as could have been expected for body weight. Similarly, we found 
that men with MetS had greater forearm muscle area (Table 1) which was entirely related to 
their higher waist circumference or BMI (Table 4). However, this should not be taken to 
imply superior muscle mass (let alone strength) in obese people, given the limitations of 
pQCT in assessing adipose infiltration which occurs interstitially, inter- and intracellularly in 
muscle (as suggested by the trend towards lower muscle density; Table 1). 
What exactly drives the non-linear relationship or plateau in the bone strength-BMI 
relationship remains unknown [16, 28]. Among the possibilities we examined, the relative 
skeletal deficits in men with MetS did not appear to be associated with adverse 
biochemical/endocrine factors or decreased physical activity/ performance. Instead, our data 
suggest that the greater bone mass was strongly determined by obesity, but obese subjects are 
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also prone to higher fasting glucose and triglyceride levels and reduced insulin sensitivity 
(Supplementary Table 2) which may in turn play a negative role and mitigate the stimulatory 
effect of body mass. Further research is however needed to investigate whether detrimental 
skeletal effects derive directly from high glucose or triglyceride levels, indirectly from 
impaired insulin signaling, or both. 
The negative association of hypertriglyceridemia with cortical bone area and strength (as 
reflected by the SSI) was explained by decreased bone width (as reflected by CSA, a measure 
of periosteal bone expansion). Even when cortical thickness or vBMD were unaffected in our 
population-based study, bone size is known to be a major determinant of bone strength. A 
recent study also reported that bone width at the femoral neck (estimated by DXA) was lower 
in MetS, although the results in men were only borderline significant [9]. In contrast, Szulc et 
al. suggested that MetS affects mainly BMC rather than bone size [5]. However, these 
previous DXA-based findings are more likely to be confounded by projectional artifacts than 
our pQCT results.  
Our study has several strengths including its large, geographically diverse random sample of 
European men. The age range was broad, but the associations of MetS and its components 
with BTMs and QUS were similar across 10-year age bands or in subgroups aged < 60 vs. ≥ 
60 years (data not shown). This is the first study of bone health in MetS with pQCT data. 
Limitations include lack of prospective analyses or fracture outcomes and, like any 
observational study, we cannot confirm causality (nor exclude reverse causation). Although 
mounting evidence supports the assumptions that obesity and insulin signaling affect the 
skeleton [17, 29, 30], our findings remain hypothesis-generating. Furthermore, measurements 
of glucose and lipids were not centralized, although these measurements are generally well 
standardized. There is considerable interest in the role of undercarboxylated osteocalcin [29], 
but only total osteocalcin was available for a randomly selected subsample of men in our 
17 
 
study. The lack of association of MetS or hypertriglyceridemia with osteocalcin (Table 2) 
likely resulted from lack of statistical power compared to PINP or β-CTX. In recent studies 
however, T2D or MetS in older men were not only associated with lower undercarboxylated 
osteocalcin but also lower total osteocalcin [27], PINP as well as β-CTX [31, 32], indicating 
that lower bone turnover in human insulin resistant states is not uniquely associated with 
undercarboxylated osteocalcin. The associations reported with dichotomized MetS 
components were confirmed in sensitivity analyses with continuous variables (data not 
shown). Thus, the lack of associations of skeletal outcomes with e.g. hypertension was not 
explained by the fact that according to the MetS cut-off, almost 80% of MetS– men still had a 
blood pressure ≥ 130/85 mmHg (Supplementary Table 1). Finally, obesity or T2D may be 
associated with spinal osteoarthritis [28] or increased cortical porosity [14, 15], but vertebral 
X-rays or high-resolution pQCT were unavailable in this study. 
In summary, MetS is associated with lower bone turnover and higher bone mass at the heel, 
hip and spine. In line with previous studies however, MetS does not seem to be a useful 
unifying construct in relation to bone health, because (i) not all components were individual 
predictors of skeletal outcomes and (ii) there was no clear cut-off for number of MetS criteria 
above which BTMs or bone mass were dose-dependently affected (Suppl. Fig. 1). Instead, we 
found differential associations of lower bone turnover mainly with correlates of insulin 
resistance, and of body mass (either by waist circumference or BMI) with higher heel BUA, 
hip and spine aBMD and radius CSA. Importantly, BMI adjustment revealed negative 
associations between markers of insulin resistance and bone mass, suggesting that the 
positive effects of bodily loads on bone may be partially offset by concomitant metabolic 
derangements. In terms of clinical implications, these findings offer a note of caution against 
false reassurance by low BTMs or absence of low BMD in men with obesity, MetS and/or 
insulin resistance. 
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Tables 
Table 1: Characteristics of men without and with metabolic syndrome. 
 MetS – 
n=2154 
MetS + 
n = 975 
P value 
Age (years) 58.3 (49.4, 68.8) 60.7 (52.0, 70.4)* 0.0001 
Weight (kg) 78.6 (71.8, 86.0) 91.7 (82.9, 101.1)* < 0.0001 
Height (cm) 173.4 (168.6, 178.5) 173.9 (168.8, 179.0) 0.20 
BMI (kg/m2) 26.2 (24.1, 28.2) 30.4 (28.1, 32.8)* < 0.0001 
Current smoker 474 [22.2%] 193 [20.0%] 0.16 
Ever smoker 1446 [68.4%] 718 [74.6%]* 0.001 
Alcohol                 every day 356 [16.6 %] 132 [13.6 %] 0.06 
5-6 days/week 163 [7.6 %] 54 [5.6 %] 
3-4 days/week 265 [12.4 %] 128 [13.2 %] 
1-2 days/week 444 [20.8 %] 204 [21.1 %] 
< once/week 578 [27.0 %] 285 [29.4 %] 
none 334 [15.6 %] 166 [17.1 %] 
Waist circumference (cm) 94.5 (88.4, 99.8) 106.5 (102.2, 113.0)* < 0.0001 
Systolic BP (mmHg) 142.0 (128.5, 155.0) 150.0 (139.0, 164.0)* < 0.0001 
Diastolic BP (mmHg) 85.0 (78.0, 93.0) 90.0 (82.0, 98.0)* < 0.0001 
HDL cholesterol (mmol/l) 1.4 (1.2, 1.7) 1.2 (1.0, 1.4)* 0.0001 
Triglycerides (mmol/l) 1.1 (0.8, 1.5) 2.0 (1.4, 2.7)* < 0.0001 
Fasting glucose (mmol/l) 5.2 (4.8, 5.5) 5.9 (5.5, 6.7)* < 0.0001 
Bone turnover markers    
PINP (µg/l) 40.0 (31.0, 51.0) 35.2 (27.4, 47.2)* < 0.0001 
Osteocalcin (µg/l) 21.6 (18.0, 26.4) 19.1 (15.3, 24.6)* < 0.0001 
β-CTX (ng/l) 339.8 (245.3, 470.4) 279.1 (183.3, 406.1)* < 0.0001 
QUS parameters n=2106 n=936  
BUA (dB/MHz) 78.9 (67.5, 92.1) 80.0 (69.1, 92.6) 0.10 
SOS (m/s) 1548.1 (1527.9, 
1571.2) 
1547.5 (1527.7, 
1567.8) 
0.73 
eBMD (g/cm2) 0.531 (0.452, 0.618) 0.536 (0.454, 0.618) 0.64 
QUI 96.1 (83.6, 109.9) 96.8 (83.9, 109.9) 0.60 
DXA: aBMD (g/cm2) n=401 n=126  
Lumbar spine (L 1-4) 1.029 (0.927, 1.126) 1.076 (0.970, 1.234)* 0.0004 
Total hip 1.002 (0.925, 1.105) 1.049 (0.950, 1.160)* 0.006 
Femoral neck 0.796 (0.724, 0.890) 0.821 (0.734, 0.927)* 0.03 
pQCT: 50% radius n=458 n=137  
Cortical bone area (mm2) 105.3 (97.0, 115.0) 108.8 (99.8, 117.0) 0.05 
Cortical thickness  (mm) 3.2 (3.0, 3.5) 3.3 (3.1, 3.6) 0.17 
Cross-sectional area (mm2) 147.2 (133.6, 161.8) 149.0 (137.5, 164.2) 0.34 
Stress strain index (mm3) 328.9 (288.9, 381.5) 344.9 (295.4, 390.8) 0.10 
Medullary area (mm2) 39.9 (32.3, 49.8) 40.0 (32.5, 46.3) 0.70 
Muscle area (mm2) 3612.5 (3184.2, 
4045.0) 
3782.0 (3448.8, 
4229.8)* 
0.0002 
Muscle density (mg/cm3) 82.9 (81.2, 84.2) 82.4 (80.4, 84.1) 0.06 
           4% radius    
Trabecular density (mg/cm3) 205.7 (178.1, 233.3) 205.8 (170.7, 234.7) 0.65 
Values are expressed as median (IQR) or n [%] 
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Table 2: Associations of MetS and its components with bone turnover markers. 1 
 Univariate Model 1† Model 2‡ Model 3 § 
β-CTX                     MetS -0.35 (-0.42, -0.27)* -0.34 (-0.42, -0.26)* - -0.26 (-0.35, -0.17)* 
Waist >102 cm -0.24 (-0.31, -0.16)* -0.24 (-0.32, -0.17)* -0.16 (-0.24, -0.08)* -0.09 (-0.19, 0.02) 
Triglycerides >150 mg/dL -0.24 (-0.32, -0.17)* -0.23 (-0.31, -0.16)* -0.16 (-0.24, -0.08)* -0.17 (-0.25, -0.09)* 
HDL <40 mg/dL -0.12 (-0.22, -0.01)* -0.14 (-0.24, -0.03)* -0.03 (-0.14, 0.08) -0.07 (-0.18, 0.04) 
Hypertension -0.13 (-0.23, -0.03)* -0.10 (-0.20, 0.00) -0.02 (-0.12, 0.09) -0.02 (-0.12, 0.08) 
Hyperglycemia -0.30 (-0.37, -0.22)* -0.30 (-0.37, -0.22)* -0.25 (-0.32, -0.17)* -0.25 (-0.33, -0.17)* 
PINP                     MetS -0.19 (-0.26, -0.11)* -0.18 (-0.26, -0.11)* - -0.20 (-0.29, -0.11)* 
Waist >102 cm -0.10 (-0.17, -0.02)* -0.10 (-0.17, -0.02)* -0.04 (-0.12, 0.04) -0.07 (-0.18, 0.03) 
Triglycerides >150 mg/dL -0.16 (-0.24, -0.08)* -0.16 (-0.24, -0.08)* -0.13 (-0.21, -0.05)* -0.16 (-0.24, -0.08)* 
HDL <40 mg/dL -0.03 (-0.14, 0.08) -0.05 (-0.16, 0.06) 0.00 (-0.12, 0.11) -0.03 (-0.14, 0.08) 
Hypertension -0.07 (-0.17, 0.02) -0.04 (-0.14, 0.06) 0.02 (-0.09, 0.12) -0.02 (-0.12, 0.09) 
Hyperglycemia -0.21 (-0.29, -0.14)* -0.21 (-0.28, -0.13)* -0.19 (-0.27, -0.11)* -0.21 (-0.29, -0.14)* 
Osteocalcin          MetS -0.26 (-0.39, -0.12)* -0.29 (-0.43, -0.15)* - -0.15 (-0.31, 0.00) 
Waist >102 cm -0.25 (-0.38, -0.12)* -0.27 (-0.40, -0.14)* -0.21 (-0.35, -0.08)* -0.08 (-0.26, 0.10) 
Triglycerides >150 mg/dL -0.20 (-0.34, -0.07)* -0.23 (-0.37, -0.09)* -0.16 (-0.31, -0.02)* -0.13 (-0.27, 0.02) 
HDL <40 mg/dL 0.01 (-0.15, 0.17) -0.06 (-0.23, 0.11) 0.07 (-0.11, 0.24) 0.02 (-0.15, 0.19) 
Hypertension -0.19 (-0.34, -0.04)* -0.13 (-0.29, 0.03) -0.04 (-0.20, 0.12) -0.03 (-0.20, 0.13) 
Hyperglycemia -0.25 (-0.38, -0.12)* -0.26 (-0.39, -0.12)* -0.20 (-0.34, -0.07)* -0.19 (-0.33, -0.06)* 
*P<0.05. Results are expressed as z-score β-coefficients (95% CI). † Model 1: Adjusted for age, centre, smoking, alcohol ‡ Model 2: Adjusted for 2 
age, centre, smoking, alcohol and other MetS components § Model 3: Adjusted for age, center, smoking, alcohol and BMI  3 
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Table 3: Associations of MetS and its components (dichotomized) with QUS parameters. 4 
  Univariate Model 1† Model 2‡ Model 3§ 
BUA                        MetS 0.10 (0.02, 0.17)* 0.11 (0.03, 0.19)* - -0.05 (-0.14, 0.03) 
Waist >102 cm 0.18 (0.11, 0.25)* 0.20 (0.13, 0.28)* 0.22 (0.14, 0.30)* 0.00 (-0.11, 0.10) 
Triglycerides >150 mg/dL 0.01 (-0.07, 0.09) 0.01 (-0.07, 0.08) -0.02 (-0.10, 0.06) -0.07 (-0.15, 0.01) 
HDL <40 mg/dL 0.04 (-0.06, 0.15) 0.05 (-0.06, 0.15) 0.01 (-0.10, 0.12) -0.01 (-0.12, 0.10) 
Hypertension -0.02 (-0.12, 0.08) 0.02 (-0.08, 0.12) 0.00 (-0.10, 0.10) -0.06 (-0.16, 0.04) 
Hyperglycemia -0.03 (-0.10, 0.05) -0.01 (-0.08, 0.07) -0.04 (-0.12, 0.04) -0.09 (-0.16, -0.01)* 
QUI                         MetS 0.06 (-0.01, 0.14) 0.08 (0.01, 0.16)* - -0.05 (-0.13, 0.04) 
Waist >102 cm 0.12 (0.04, 0.19)* 0.14 (0.07, 0.22)* 0.16 (0.08, 0.24)* -0.02 (-0.13, 0.08) 
Triglycerides >150 mg/dL 0.00 (-0.08, 0.08) 0.00 (-0.08, 0.07) -0.02 (-0.10, 0.06) -0.07 (-0.15, 0.01) 
HDL <40 mg/dL 0.03 (-0.08, 0.13) 0.03 (-0.08, 0.14) 0.00 (-0.11, 0.11) -0.01 (-0.12, 0.09) 
Hypertension -0.06 (-0.16, 0.04) 0.00 (-0.10, 0.10) -0.01 (-0.11, 0.09) -0.07 (-0.17, 0.04) 
Hyperglycemia -0.04 (-0.11, 0.03) -0.01 (-0.08, 0.06) -0.03 (-0.11, 0.05) -0.07 (-0.15, 0.00) 
*P<0.05. Results are expressed as z-score β-coefficients (95% CI). † Model 1: Adjusted for age, centre, smoking, alcohol ‡ Model 2: Adjusted for 5 
age, centre, smoking, alcohol and other MetS components § Model 3: Adjusted for age, center, smoking, alcohol and BMI 6 
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Table 4: Associations of MetS and its components (dichotomized) with aBMD and pQCT parameters. 8 
  Univariate Model 1† Model 2‡ Model 3§ 
 aBMD (g/cm2) L1-4:           MetS 0.41 (0.21, 0.61)* 0.36 (0.16, 0.57)* - 0.07 (-0.15, 0.29) 
Waist >102 cm 0.48 (0.29, 0.67)* 0.45 (0.26, 0.64)* 0.42 (0.22, 0.62)* 0.07 (-0.19, 0.33) 
Triglycerides >150 mg/dL 0.04 (-0.15, 0.23) 0.03 (-0.16, 0.22) -0.10 (-0.30, 0.09) -0.12 (-0.30, 0.07) 
HDL <40 mg/dL 0.15 (-0.15, 0.45) 0.11 (-0.20, 0.42) 0.02 (-0.29, 0.33) -0.04 (-0.34, 0.26) 
Hypertension 0.27 (0.03, 0.51)* 0.25 (0.00, 0.49) 0.15 (-0.10, 0.40) 0.10 (-0.15, 0.34) 
Hyperglycemia 0.38 (0.18, 0.58)* 0.32 (0.12, 0.52)* 0.24 (0.04, 0.44)* 0.19 (-0.01, 0.39) 
aBMD (g/cm2) FN:              MetS 0.24 (0.04, 0.44)* 0.25 (0.06, 0.45)* - -0.12 (-0.33, 0.09) 
Waist >102 cm 0.37 (0.18, 0.55)* 0.44 (0.25, 0.62)* 0.43 (0.23, 0.62)* -0.06 (-0.31, 0.19) 
Triglycerides >150 mg/dL -0.03 (-0.22, 0.16) -0.10 (-0.29, 0.09) -0.23 (-0.42, -0.04)* -0.26 (-0.44, -0.08)* 
HDL <40 mg/dL 0.13 (-0.17, 0.42) 0.10 (-0.20, 0.41) 0.06 (-0.24, 0.37) -0.06 (-0.34, 0.23) 
Hypertension -0.04 (-0.28, 0.20) 0.10 (-0.15, 0.34) -0.01 (-0.25, 0.23) -0.07 (-0.31, 0.16) 
Hyperglycemia 0.26 (0.07, 0.46)* 0.33 (0.13, 0.52)* 0.28 (0.08, 0.48)* 0.18 (-0.01, 0.37) 
 aBMD (g/cm2) Total hip:   MetS 0.31 (0.11, 0.51)* 0.34 (0.13, 0.54)* - -0.09 (-0.30, 0.12) 
Waist >102 cm 0.49 (0.30, 0.68)* 0.55 (0.36, 0.74)* 0.54 (0.35, 0.74)* 0.02 (-0.22, 0.27) 
Triglycerides >150 mg/dL -0.01 (-0.20, 0.18) -0.04 (-0.23, 0.15) -0.19 (-0.38, 0.00) -0.23 (-0.41, -0.05)* 
HDL <40 mg/dL 0.12 (-0.18, 0.43) 0.16 (-0.15, 0.47) 0.08 (-0.23, 0.39) -0.03 (-0.32, 0.26) 
Hypertension 0.04 (-0.20, 0.28) 0.11 (-0.13, 0.36) -0.01 (-0.25, 0.24) -0.10 (-0.34, 0.13) 
Hyperglycemia 0.31 (0.11, 0.50)* 0.35 (0.15, 0.55)* 0.28 (0.08, 0.48)* 0.17 (-0.02, 0.36) 
pQCT: 50% radius     
CSA                                          
Waist >102 cm 0.36 (0.18, 0.53)* 0.34 (0.16, 0.53)* 0.41 (0.22, 0.60)* 0.22 (-0.03, 0.47) 
Triglycerides >150 mg/dL -0.18 (-0.36, 0.00)* -0.18 (-0.37, 0.00) -0.21 (-0.40, -0.02)* -0.26 (-0.44, -0.07)* 
HDL <40 mg/dL -0.17 (-0.44, 0.10) -0.18 (-0.46, 0.10) -0.20 (-0.48, 0.08) -0.23 (-0.51, 0.05) 
Hypertension -0.12 (-0.34, 0.11) -0.16 (-0.40, 0.07) -0.22 (-0.45, 0.01) -0.28 (-0.52, -0.04)* 
Hyperglycemia 0.12 (-0.07, 0.30) 0.09 (-0.10, 0.28) 0.07 (-0.13, 0.26) 0.03 (-0.17, 0.23) 
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Cortical thickness                    
Waist >102 cm 0.21 (0.03, 0.38)* 0.28 (0.10, 0.47)* 0.27 (0.08, 0.46)* 0.13 (-0.12, 0.38) 
Triglycerides >150 mg/dL 0.06 (-0.12, 0.24) 0.03 (-0.15, 0.21) -0.02 (-0.22, 0.17) -0.06 (-0.24, 0.13) 
HDL <40 mg/dL 0.08 (-0.21, 0.36) 0.11 (-0.18, 0.39) 0.06 (-0.24, 0.35) 0.03 (-0.25, 0.32) 
Hypertension -0.04 (-0.27, 0.18) 0.08 (-0.15, 0.31) 0.03 (-0.21, 0.26) -0.01 (-0.25, 0.22) 
Hyperglycemia -0.02 (-0.22, 0.17) 0.04 (-0.15, 0.24) 0.01 (-0.19, 0.20) -0.04 (-0.23, 0.16) 
Cortical bone area                   
Waist >102 cm 0.40 (0.23, 0.58)* 0.45 (0.27, 0.63)* 0.48 (0.29, 0.67)* 0.25 (0.00, 0.49) 
Triglycerides >150 mg/dL -0.08 (-0.26, 0.10) -0.10 (-0.28, 0.08) -0.17 (-0.36, 0.02) -0.23 (-0.41, -0.05)* 
HDL <40 mg/dL -0.03 (-0.31, 0.25) -0.01 (-0.30, 0.28) -0.05 (-0.34, 0.24) -0.12 (-0.40, 0.17) 
Hypertension -0.06 (-0.28, 0.17) 0.00 (-0.23, 0.23) -0.08 (-0.31, 0.15) -0.14 (-0.38, 0.09) 
Hyperglycemia 0.04 (-0.15, 0.23) 0.07 (-0.13, 0.26) 0.03 (-0.16, 0.22) -0.04 (-0.24, 0.15) 
Stress strain index                   
Waist >102 cm 0.40 (0.23, 0.58)* 0.42 (0.24, 0.60)* 0.48 (0.30, 0.67)* 0.30 (0.05, 0.55)* 
Triglycerides >150 mg/dL -0.15 (-0.33, 0.03) -0.15 (-0.34, 0.03) -0.19 (-0.38, -0.01)* -0.26 (-0.44, -0.07)* 
HDL <40 mg/dL -0.20 (-0.48, 0.07) -0.20 (-0.49, 0.08) -0.23 (-0.51, 0.06) -0.29 (-0.58, -0.01)* 
Hypertension -0.13 (-0.35, 0.10) -0.11 (-0.34, 0.12) -0.18 (-0.40, 0.05) -0.23 (-0.47, 0.00) 
Hyperglycemia -0.01 (-0.20, 0.17) 0.00 (-0.19, 0.19) -0.02 (-0.21, 0.17) -0.08 (-0.28, 0.11) 
Muscle area                              
Waist >102 cm 0.56 (0.38, 0.73)* 0.68 (0.51, 0.84)* 0.61 (0.44, 0.79)* -0.23 (-0.44, -0.03)* 
Triglycerides >150 mg/dL 0.17 (-0.01, 0.35) 0.13 (-0.05, 0.30) -0.06 (-0.23, 0.11) -0.13 (-0.29, 0.02) 
HDL <40 mg/dL 0.30 (0.02, 0.59)* 0.32 (0.04, 0.59)* 0.20 (-0.07, 0.47) 0.08 (-0.16, 0.32) 
Hypertension 0.07 (-0.15, 0.30) 0.32 (0.11, 0.54)* 0.21 (-0.01, 0.42) 0.00 (-0.19, 0.20) 
Hyperglycemia 0.07 (-0.12, 0.26) 0.22 (0.04, 0.41)* 0.09 (-0.08, 0.27) -0.05 (-0.21, 0.12) 
*P<0.05. Results are expressed as z-score β-coefficients (95% CI). † Model 1: Adjusted for age, centre, smoking, alcohol ‡ Model 2: Adjusted for 9 
age, centre, smoking, alcohol and other MetS components § Model 3: Adjusted for age, center, smoking, alcohol and BMI10 
 
